Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | F13A1 | P00488 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10030732 | 0.91 | EPHX2 (0.48) | HPGDEPHX2LMNAPKMTAAR1 | |
| SCHEMBL10030729 | 0.89 | HPGD (0.56) | HPGDEPHX2TAAR1HDAC1HDAC2 | |
| SCHEMBL19617998 | 0.89 | HPGD (0.56) | HPGDEPHX2TAAR1HDAC1HDAC2 | |
| SCHEMBL10030727 | 0.89 | MEN1 (0.57) | HPGDEPHX2SIRT2FAAH | |
| SCHEMBL10030733 | 0.84 | HPGD (0.47) | HPGDEPHX2SIRT2CNR2 | |
| SCHEMBL873318 | 0.83 | DGKA (0.66) | HPGDEPHX2 | |
| SCHEMBL873938 | 0.83 | DGKA (0.66) | HPGDEPHX2 | |
| SCHEMBL3506704 | 0.83 | DGKA (0.66) | HPGDEPHX2 | |
| SCHEMBL10766992 | 0.83 | DGKA (0.66) | HPGDEPHX2 | |
| SCHEMBL28381584 | 0.83 | DGKA (0.66) | HPGDEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210922-A1 | 3D PRINTING SYSTEM COMPRISING SOLID BUILD INK COMPRISING COLORANT | XEROX CORPORATION | 2017-07-27 | — | — | US | disclosed |
| US-20170210922-A1 | 3D PRINTING SYSTEM COMPRISING SOLID BUILD INK COMPRISING COLORANT | XEROX CORPORATION | 2017-07-27 | — | — | US | disclosed |
| US-9676952-B2 | 3D printing system comprising solid build ink comprising colorant | XEROX CORPORATION (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676952-B2 | 3D printing system comprising solid build ink comprising colorant | XEROX CORPORATION (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160244628-A1 | 3D PRINTING SYSTEM COMPRISING SOLID BUILD INK COMPRISING COLORANT | XEROX CORPORATION | 2016-08-25 | — | — | US | disclosed |
| US-20160244628-A1 | 3D PRINTING SYSTEM COMPRISING SOLID BUILD INK COMPRISING COLORANT | XEROX CORPORATION | 2016-08-25 | — | — | US | disclosed |
| US-9012527-B2 | Curable compositions for three-dimensional printing | XEROX CORPORATION (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012527-B2 | Curable compositions for three-dimensional printing | XEROX CORPORATION (US) | 2015-04-21 | — | — | US | disclosed |
| US-20140171537-A1 | Orange Curable Ink | XEROX CORPORATION (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140171537-A1 | Orange Curable Ink | XEROX CORPORATION (US) | 2014-06-19 | — | — | US | disclosed |
| US-8084637-B2 | Amide gellant compounds with aromatic end groups | XEROX CORPORATION (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084637-B2 | Amide gellant compounds with aromatic end groups | XEROX CORPORATION (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110263769-A1 | Phase Change Inks Containing Amide Gellant Compounds With Aromatic End Groups | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262711-A1 | CURABLE COMPOSITIONS FOR THREE-DIMENSIONAL PRINTING | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262643-A1 | INK COMPOSITIONS AND METHODS | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262711-A1 | CURABLE COMPOSITIONS FOR THREE-DIMENSIONAL PRINTING | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263890-A1 | Amide Gellant Compounds With Aromatic End Groups | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262643-A1 | INK COMPOSITIONS AND METHODS | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263769-A1 | Phase Change Inks Containing Amide Gellant Compounds With Aromatic End Groups | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263890-A1 | Amide Gellant Compounds With Aromatic End Groups | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263890-A1 | Amide Gellant Compounds With Aromatic End Groups | NAT1, AGPAT2, CCNT1 | HPGD 3248/4885EPHX2 1171/4885LMNA 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.